Welcome to our dedicated page for Biomx SEC filings (Ticker: PHGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BiomX Inc. (PHGE) SEC filings document a public company whose reported focus has shifted from legacy phage therapy development toward defense, security, and critical infrastructure technology. Recent filings include quarterly reports, amended annual report material, current reports on Form 8-K, shareholder voting disclosures, material agreements, capital-structure items, governance matters, and risk-factor disclosures.
PHGE’s 10-Q filings are important because BiomX reports as a single operating segment and presents its financial information on a consolidated basis. The quarterly filing also states that the company has incurred significant losses and negative cash flows from operations and that these factors raise substantial doubt about its ability to continue as a going concern.
BiomX 8-K filings are especially relevant because recent material-event reports describe the Zorronet acquisition, shareholder approvals, and a framework supply agreement involving Israel Railways. These filings provide details on Zorronet’s AI-powered computer vision, autonomous surveillance, threat detection, object recognition, perimeter intrusion identification, and command-and-control integrations.
Annual reports on 10-K and amended annual reports on 10-K/A provide governance, compensation, equity plan, and business-history context. Proxy materials show shareholder voting matters. Form 4 insider transaction filings, when filed, identify changes in beneficial ownership by company insiders. For PHGE, the most relevant filing themes are Zorronet and DFSL operating disclosures, legacy phage therapy background, going-concern language, governance changes, and material agreements tied to defense and infrastructure markets.
BiomX Inc. has called an extraordinary special meeting on April 10, 2026 to seek stockholder approval of a new 2026 Equity Incentive Plan and a related adjournment proposal. As of the March 23, 2026 record date, 6,543,516 shares of common stock were outstanding and entitled to vote.
The 2026 Plan would authorize an initial reserve of 1,390,000 shares of common stock, replacing the 2019 omnibus plan for new grants, and includes an evergreen mechanism that can add 4% of outstanding shares each January 1 from 2027 through 2036. The plan allows options, RSUs, restricted stock, SARs, performance and other stock-based awards, with minimum one-year vesting (subject to a 5% carve-out), no repricing without stockholder approval, and double-trigger vesting on certain terminations after a change in control. The Board unanimously recommends voting “FOR” both the plan and the adjournment authority.
BiomX Inc. entered into an amendment to a previously issued warrant covering up to 3,300,000 shares of common stock that were issued with 3,300 shares of Series Y Convertible Preferred Stock sold in December 2025. The amendment shortens the warrant’s term so it now expires on December 31, 2026, reduces the exercise price from $2.00 to $1.00 per share, and changes the cashless exercise formula to reference the lowest VWAP over the five trading days before exercise notice. The number of underlying warrant shares remains unchanged. In a CEO letter, BiomX describes this as part of a broader financial and strategic reset aimed at simplifying its capital structure, resolving long-dated warrant overhang, cutting costs including closing a Maryland facility, and exploring a pivot toward sectors such as advanced technologies and defense-related applications.
BiomX Inc. director and 10% owner Yeganeh Reuven, through Pyu Pyu Capital LLC, converted Series Y Convertible Preferred Stock into Common Stock at a conversion price of $2.00 per share and then sold the resulting shares in private transactions.
Pyu Pyu Capital LLC received 450,000 and 530,000 Common shares upon conversion and sold all 980,000 shares at $5.00 per share in private deals. It also sold 5,000,000 Common Stock Purchase Warrants in private transactions at prices between $4.76 and $5.24 per warrant share, leaving no Common Stock or warrants reported as held after these transactions.
BiomX Inc. director and 10% owner Yeganeh Reuven, through Pyu Pyu Capital LLC, reported a series of conversions and sales of the company’s stock. Pyu Pyu converted Series Y Convertible Preferred Stock into a total of 670,000 shares of Common Stock at $2.00 per share, then sold those 670,000 Common shares in private transactions at $5.00 per share over March 11–13, 2026. The filing notes the securities are directly owned by Pyu Pyu Capital LLC and may be deemed beneficially owned by Reuven as its sole member, with Reuven disclaiming beneficial ownership except to the extent of his pecuniary interest.
BiomX Inc. reported the final results of a special stockholder meeting held on March 11, 2026. As of the February 3, 2026 record date, 1,593,516 shares of common stock were outstanding and all 1,593,516 votes were represented in person or by proxy.
Stockholders approved two proposals described in the company’s February 13, 2026 proxy statement. One proposal received 528,511 votes for, 23,714 against, and 4,753 abstentions. The other received 524,578 votes for, 31,778 against, and 622 abstentions. No further adjournment of the meeting was required.
BiomX Inc. reported significant leadership changes. On March 4, 2026, Jonathan Solomon resigned from the board, all board committees, and his roles as Chief Executive Officer and Chief Principal Officer, effective immediately. The company states his resignation did not result from any disagreement over operations, policies, or practices.
On the same date, Chairman of the Board Dr. Russell Greig resigned from the board and its committees, also without any stated disagreement. The board appointed Amir Shalom as a Class I director, deemed independent under NYSE American rules, with his term expiring at the 2027 annual meeting, and he will receive standard director compensation and an indemnification agreement.
To fill the CEO vacancy, the board appointed Michael Oster as Chief Executive Officer effective March 4, 2026, noting his extensive experience in strategy, M&A, and operational leadership. As of this report, no compensatory arrangement with Mr. Oster has been entered into. Effective March 5, 2026, the board also reassigned members and chairs of its Audit, Compensation, and Nominating and Corporate Governance Committees.
BiomX Inc. director Bidas Liat Cohavi has filed a Form 3, which is an initial statement of insider status at the company. The data provided shows no buy, sell, acquisition, or disposition transactions, only that Cohavi is currently serving as a director.
BiomX Inc. reported significant leadership changes and a delayed shareholder vote. On February 24, 2026, its Chief Financial Officer and Chief Development Officer resigned, and on February 25, 2026, three directors resigned from the Board and all committees. The company stated that none of these resignations involved any disagreement over operations, policies, or practices.
On February 27, 2026, the Board appointed David Rokach as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, citing his executive, governance and investment experience. Separately, a Special Meeting of Stockholders convened on February 25, 2026 was adjourned due to lack of quorum and is expected to reconvene on March 11, 2026, with the record date remaining February 3, 2026 and no changes to the proposals.
BiomX Inc. reported changes to its Board of Directors. On February 19, 2026, Alan Moses resigned from the Board for personal reasons and indicated he had no disagreements with the company regarding its operations, policies, or practices.
On February 25, 2026, the Board appointed Guy Arieli as a Class I director with a term expiring at the 2027 annual meeting and Shaked Ran as a Class III director with a term expiring at the 2026 annual meeting, filling two existing vacancies. Both are experienced investment and pension advisory professionals, were deemed independent under NYSE American rules, and will receive standard director compensation with prorated annual cash fees. The company will enter into indemnification agreements with each on substantially the same terms as for its other directors.
BiomX Inc. is a clinical-stage company developing bacteriophage therapies targeting harmful bacteria in chronic conditions such as diabetic foot infections and osteomyelitis. The company has no approved products and has never generated revenue from product sales.
In December 2025 BiomX discontinued development of its cystic fibrosis candidate BX004 after adverse events and resource constraints, and later began insolvency proceedings for its Israeli subsidiary BiomX Ltd., which previously housed core operations. A court-appointed trustee now controls that subsidiary, and BiomX no longer treats it as an asset.
To address severe liquidity pressure, BiomX entered a Securities Purchase Agreement for 3,300 shares of Series Y Convertible Preferred Stock and warrants, for $3.0 million in gross proceeds. If stockholders approve the deal, the investor is expected to become the majority common stockholder and could change the company’s business, strategy and objectives. The company’s risk factors highlight substantial doubt about its ability to continue as a going concern and emphasize that its future depends heavily on securing this stockholder approval and further financing.